NASDAQ · DTIL
Healthcare · Biotechnology
$6.95
Down-$0.11 (-1.56%)
Updated Nov 3, 2026, 1:49 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DTIL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
DTIL closed at $6.95 after 21 trading sessions, up 10.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $7.06 | $7.42 | $6.82 | $6.95 | 167.91K |
| Oct 30, 2026 | $7.31 | $7.42 | $6.97 | $7.06 | 108.93K |
| Oct 29, 2026 | $7.50 | $7.82 | $7.37 | $7.44 | 165.74K |
| Oct 28, 2026 | $6.76 | $7.50 | $6.66 | $7.47 | 189.67K |
| Oct 27, 2026 | $6.39 | $6.81 | $6.29 | $6.79 | 164.25K |
| Oct 26, 2026 | $6.68 | $6.8763 | $6.37 | $6.41 | 266.68K |
| Oct 23, 2026 | $6.73 | $6.73 | $6.29 | $6.64 | 275.53K |
| Oct 22, 2026 | $6.70 | $6.925 | $6.58 | $6.78 | 132.43K |
| Oct 21, 2026 | $6.62 | $6.86 | $6.545 | $6.71 | 231.04K |
| Oct 20, 2026 | $6.09 | $6.67 | $6.09 | $6.56 | 213.66K |
| Oct 19, 2026 | $5.80 | $6.21 | $5.77 | $6.19 | 176.47K |
| Oct 16, 2026 | $6.18 | $6.18 | $5.72 | $5.77 | 300.25K |
| Oct 15, 2026 | $6.04 | $6.20 | $5.98 | $6.17 | 246.14K |
| Oct 14, 2026 | $6.05 | $6.25 | $5.92 | $6.03 | 294.25K |
| Oct 13, 2026 | $6.51 | $6.55 | $6.05 | $6.10 | 326.68K |
| Oct 12, 2026 | $6.71 | $6.7294 | $6.4482 | $6.53 | 228.78K |
| Oct 9, 2026 | $6.43 | $6.92 | $6.35 | $6.72 | 263.69K |
| Oct 8, 2026 | $6.25 | $6.53 | $6.19 | $6.43 | 332.55K |
| Oct 7, 2026 | $6.20 | $6.38 | $6.11 | $6.25 | 162.52K |
| Oct 6, 2026 | $6.36 | $6.40 | $6.105 | $6.20 | 190.96K |
| Oct 5, 2026 | $6.36 | $6.375 | $5.975 | $6.31 | 219.03K |
The latest Smart Investors Daily articles mentioning DTIL.
Company
Market Activity
Research & News
DTIL research
Company profile and research snapshot.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 9, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 9, 2026 | Oppenheimer | Outperform | — |
| May 27, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
DURHAM, N.C., October 29, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2026 and provide a business update on Tuesday, November 3, 2026.
Yahoo · Oct 8, 2026
DURHAM, N.C., October 08, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77th annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2026 will take place November 5-9 in Denv
Benzinga · Aug 27, 2026
iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts, saying the therapy
Benzinga · Aug 24, 2026
PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durably improve function. This novel approach, aiming to restore near full-length dystrophin, is applicable for up to 60% of DMD
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DTIL.
